Long-term Safety and Tolerability of AFFITOPE AD01
NCT00711139 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22
Last updated 2010-05-27
Summary
The purpose of this study is to assess the long-term tolerability and -safety of AFFITOPE AD01 applied during AFFiRiS 001
Conditions
Sponsors & Collaborators
-
Affiris AG
lead INDUSTRY
Principal Investigators
-
Markus Mueller, Univ. Prof. · Medical University of Vienna
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-06-30
- Primary Completion
- 2009-11-30
- Completion
- 2009-11-30
Countries
- Austria
Study Locations
More Related Trials
-
Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease
NCT00495417 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability of AFFITOPE AD03
NCT01309763 ·Status: COMPLETED ·Phase: PHASE1
-
Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006
NCT02008513 ·Status: TERMINATED ·Phase: PHASE2
-
Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease
NCT01357629 ·Status: TERMINATED
-
Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease
NCT00633841 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety and Tolerability Study of ABT-126 in Elderly
NCT00867399 ·Status: COMPLETED ·Phase: PHASE1
-
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
NCT01238991 ·Status: TERMINATED ·Phase: PHASE2
-
Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia
NCT00095719 ·Status: COMPLETED ·Phase: PHASE3
-
Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease
NCT00842816 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
NCT01549834 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease
NCT01482845 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study
NCT00809510 ·Status: TERMINATED ·Phase: PHASE2
-
Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia
NCT01327859 ·Status: COMPLETED ·Phase: PHASE3
-
Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care
NCT03456349 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil
NCT01406145 ·Status: COMPLETED ·Phase: PHASE1
-
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
NCT05744401 ·Status: TERMINATED ·Phase: PHASE2
-
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
NCT06304883 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
NCT05328115 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
NCT01690195 ·Status: TERMINATED ·Phase: PHASE2
-
Alzheimer's Disease Acitretin Medication
NCT01078168 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease
NCT00948909 ·Status: COMPLETED ·Phase: PHASE2
-
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
NCT02162264 ·Status: COMPLETED
-
To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.
NCT00151502 ·Status: COMPLETED ·Phase: PHASE3
-
Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.
NCT00731224 ·Status: COMPLETED ·Phase: PHASE4
-
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
NCT01369225 ·Status: COMPLETED ·Phase: PHASE1